Columbia, MDNCT07816666Now EnrollingIRB Ready

Platinum-sensitive Relapsed Epithelial Ovarian Cancer Clinical Trial in Columbia, MD

Access cutting-edge platinum-sensitive relapsed epithelial ovarian cancer treatment through this phase 3 clinical trial at a research site in Columbia. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Columbia location

Preparing your pre-screening questions…

Expert Care in Columbia

Access platinum-sensitive relapsed epithelial ovarian cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related platinum-sensitive relapsed epithelial ovarian cancer treatment provided free

Apply for This Columbia Location

Check if you qualify for this platinum-sensitive relapsed epithelial ovarian cancer clinical trial in Columbia, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Columbia

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Columbia site if eligible
  4. 4Begin participation

About This Platinum-sensitive Relapsed Epithelial Ovarian Cancer Study in Columbia

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
Provision of an archival FFPE tumour sample
Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
Participants who received 4-6 cycles of PBC during the induction phase of their current line of treatment.
Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
Participants with non-progressive disease upon completion of PBC in their current line of treatment.
Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).

Exclusion Criteria

Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.
Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Columbia?

Yes, this clinical trial (NCT07816666) has an active research site in Columbia, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Platinum-sensitive Relapsed Epithelial Ovarian Cancer Treatment Options in Columbia, MD

If you're searching for platinum-sensitive relapsed epithelial ovarian cancer treatment options in Columbia, MD, this clinical trial (NCT07816666) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Columbia research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced platinum-sensitive relapsed epithelial ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all platinum-sensitive relapsed epithelial ovarian cancer clinical trials near you to find additional studies recruiting in your area.

More Ovarian Cancer Trials in Columbia, MD

See all ovarian cancer clinical trials recruiting in Columbia — not just this study.

Browse Ovarian Cancer Trials in Columbia →

Browse More Trials by Condition

Ovarian Cancer TrialsAntiphospholipid Syndrome TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Columbia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Columbia, MD